Actavis' Namenda switch exceeds expectations, and its ability to supply new version

Usually, exceeding expectations when it comes to a sales goal is a good thing. But in the case of Actavis ($ACT) and its forced switch of patients to a once-daily version of its Alzheimer's treatment Namenda, it is posing some problems--supply problems. The company announced earlier that it would stop production in August of the original version, a move that would leave patients no choice but to switch to the patent protected extended release product, and so keep most of the sales. It has since said it will continue to make it into the fall and conceded to Bloomberg that it is having trouble keeping up with demand for the new capsule. Story | More

Suggested Articles

After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.